These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2314551)

  • 1. Progressive renal failure despite discontinuation of mefenamic acid.
    Itami N; Akutsu Y; Yasoshima K; Tochimaru H; Takekoshi Y; Matsumoto S
    Nephron; 1990; 54(3):281-2. PubMed ID: 2314551
    [No Abstract]   [Full Text] [Related]  

  • 2. Mefenamic acid nephropathy.
    Robertson CE; Ford MJ; Van Someren V; Dlugolecka M; Prescott LF
    Lancet; 1980 Aug; 2(8188):232-3. PubMed ID: 6105396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal anti-inflammatory drugs in elderly people. Mefenamic acid is more dangerous than most.
    Grant DJ; MacConnachie AM
    BMJ; 1995 Aug; 311(7001):392. PubMed ID: 7640566
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience.
    Lionaki S; Vlachopanos G; Georgalis A; Liapis G; Skalioti C; Zavos G; Boletis JN
    Ren Fail; 2015 Jun; 37(5):777-83. PubMed ID: 25715638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible renal failure following mefenamic acid.
    Boletis J; Williams AJ; Shortland JR; Brown CB
    Nephron; 1989; 51(4):575-6. PubMed ID: 2739843
    [No Abstract]   [Full Text] [Related]  

  • 6. Focal segmental glomerulosclerosis and progressive renal failure associated with a unilateral kidney.
    Thorner PS; Arbus GS; Celermajer DS; Baumal R
    Pediatrics; 1984 Jun; 73(6):806-10. PubMed ID: 6728582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis.
    Gossmann J; Scheuermann EH; Porubsky S; Kachel HG; Geiger H; Hauser IA
    Transpl Int; 2007 Jun; 20(6):558-62. PubMed ID: 17433091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
    Han KH; Kim SH
    Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
    Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
    Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of primary focal segmental glomerulosclerosis (FSGS) in Turkish children: a report from the Turkish Pediatric Nephrology FSGS Study Group.
    Beşbaş N; Ozaltin F; Emre S; Anarat A; Alpay H; Bakkaloğlu A; Baskin E; Buyan N; Dönmez O; Düşünsel R; Ekim M; Göko F; Gür-Güven A; Kavukçu S; Mir S; Sönmez F
    Turk J Pediatr; 2010; 52(3):255-61. PubMed ID: 20718182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation.
    Chitalia VC; Wells JE; Robson RA; Searle M; Lynn KL
    Kidney Int; 1999 Dec; 56(6):2236-42. PubMed ID: 10594800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study.
    Bazzi C; Petrini C; Rizza V; Napodano P; Paparella M; Arrigo G; Pisano L; D'Amico G
    Am J Kidney Dis; 2003 Feb; 41(2):328-35. PubMed ID: 12552493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mefenamic acid nephropathy: further evidence.
    Drury PL; Asirdas LG; Bulger GV
    Br Med J (Clin Res Ed); 1981 Mar; 282(6267):865-6. PubMed ID: 6783206
    [No Abstract]   [Full Text] [Related]  

  • 14. Living-related-donor kidney transplantation outcome in recipients with primary focal-segmental glomerulosclerosis.
    Refaie A; Sobh M; Moustafa F; Bakr MA; El-Mekresh M; Farahat S; Ghoneim MA
    Am J Nephrol; 1999; 19(1):55-9. PubMed ID: 10085451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 19-year-old man with hypertension, proteinuria, and renal insufficiency.
    Broumand V; Paueksakon P; Lewis JB; Nadeau J; Fogo A
    Am J Kidney Dis; 1999 Oct; 34(4):768-74. PubMed ID: 10516364
    [No Abstract]   [Full Text] [Related]  

  • 16. [Retrospective follow-up control of progressive renal failure with logarithmic transformation of the serum creatinine concentration].
    Lachhein L; Welzel M; Kielstein R; Beyer H
    Z Urol Nephrol; 1986 Feb; 79(2):67-71. PubMed ID: 3705779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of orthostatic proteinuria to focal and segmental glomerulosclerosis.
    Berns JS; McDonald B; Gaudio KM; Siegel NJ
    Clin Pediatr (Phila); 1986 Mar; 25(3):165-6. PubMed ID: 3948459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal glomerulosclerosis manifested with nephrotic syndrome.
    Tsau YK; Chen CH; Tsai WS; Sheu JN; Kuo PJ; Hsu HC
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1989; 30(6):401-7. PubMed ID: 2637621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mefenamic acid nephropathy.
    Woods KL; Michael J
    Br Med J (Clin Res Ed); 1981 May; 282(6274):1471. PubMed ID: 6784867
    [No Abstract]   [Full Text] [Related]  

  • 20. Galactose therapy reduces proteinuria in patients with recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Robson K; Hill P; Langsford D; Dwyer K; Goodman D; Langham R
    Nephrology (Carlton); 2015 Mar; 20 Suppl 1():13-6. PubMed ID: 25807852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.